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Introduction
Mammalian oocyte growth and development is critically
dependent on a functional two-way communication axis
between the germ cell and its companion somatic cells, the
ovarian granulosa cells (GCs). The cellular and molecular
processes involved are poorly understood but it is evident that
communication between the oocyte and somatic cells can be
in the form of direct gap-junctional communication and/or
paracrine signalling via soluble oocyte-secreted factors
(OSFs). During the course of folliculogenesis a highly
specialised subset of GCs differentiate in the immediate
vicinity of the oocyte, called cumulus cells (CCs), and through
gap-junctional communication, these cells establish intimate
metabolic contact with each other and with the oocyte, forming
the cumulus-oocyte complex. It has long been recognised that
GCs and CCs transmit the endocrine and local ovarian signals
responsible for nurturing growth and development of the
oocyte. This communication is essential for oogenesis and
acquisition of oocyte developmental competence. By contrast,
it has only more recently become recognised that oocyte
paracrine signalling to GCs/CCs is a fundamental process that
regulates ovarian folliculogenesis and has profound effects on
fertility if disturbed (Dong et al., 1996; McNatty et al., 2004).
Oocytes regulate folliculogenesis by modulating a broad
range of GC and CC functions associated with somatic cell
growth and differentiation, primarily achieved through the
secretion of soluble growth factors acting locally on these cells,
rather than by gap-junctional signalling (reviewed in Eppig,
2001; Gilchrist et al., 2004a). Some of the GC and CC
functions regulated by OSFs include: promotion of cellular
growth (Eppig et al., 2002; Gilchrist et al., 2001; Vanderhyden
et al., 1992) and prevention of death (Hussein et al., 2005);
modulation of steroidogenesis (Vanderhyden et al., 1993); CC
expansion (Buccione et al., 1990; Salustri et al., 1990); inhibin,
activin and follistatin synthesis (Glister et al., 2003; Lanuza et
al., 1999); as well as modulation of kit-ligand (Joyce et al.,
Oocytes regulate follicle growth by secreting paracrine
growth factors that act on neighbouring granulosa cells
(GCs). Those factors identified to date are mainly members
of the transforming growth factor- (TGF) superfamily,
but little is known about which specific receptor/signalling
system(s) they employ. This study was conducted to
determine the requisite pathways utilised by oocytes to
promote GC proliferation. We used an established oocyte-
secreted mitogen bioassay, where denuded mouse oocytes
are co-cultured with mural GCs. Oocytes, growth
differentiation factor-9 (GDF9), TGF1 and activin-A all
promoted GC DNA synthesis, but bone-morphogenetic
protein 6 (BMP6) did not. Subsequently, we tested
the capacity of various TGF superfamily receptor
ectodomains (ECD) to neutralise oocyte- or specific growth
factor-stimulated GC proliferation. The BMP type-II
receptor (BMPR-II) ECD antagonised oocyte and GDF9
bioactivity dose-dependently, but had no or minimal effect
on TGF1 and activin-A bioactivity, demonstrating its
specificity. The TGFR-II, activinR-IIA and activinR-IIB
ECDs all failed to neutralise oocyte- or GDF9-stimulated
GC DNA synthesis, whereas they did antagonise the
activity of their respective native ligands. An activin
receptor-like kinase (ALK) 4/5/7 inhibitor, SB431542, also
antagonised both oocyte and GDF9 bioactivity in a dose-
dependent manner. Consistent with these findings, oocytes,
GDF9 and TGF1 all activated SMAD2/3 reporter
constructs in transfected GC, and led to phosphorylation
of SMAD2 proteins in treated cells. Surprisingly, oocytes
did not activate the SMAD1/5/8 pathway in transfected
GCs although exogenous BMP6 did. This study indicates
that oocyte paracrine factors primarily utilise a similar
signalling pathway first identified for GDF9 that employs
an unusual combination of TGF superfamily receptors,
the BMPR-II and a SMAD2/3 stimulatory ALK (4, 5 or 7),
for transmitting their mitogenic actions in GC. This cell-
signalling pathway may also have relevance in the
hypothalamic-pituitary axis and in germ-somatic cell
interactions in the testis.
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2000), luteinizing hormone receptor (Eppig et al., 1997) and
urokinase plasminogen activator expression (Canipari et al.,
1995). By controlling the developmental pathway of its
neighbouring somatic cells, the oocyte actively regulates its
own microenvironment (Eppig et al., 1997; Li et al., 2000).
Understanding oocyte control of GC/CC function and of
folliculogenesis in general is important because altered
expression of known oocyte paracrine factors can lead to
sterility or increased fecundity in a species-dependent manner
(McNatty et al., 2004).
The molecular basis of the paracrine communication axis
from oocytes to GCs/CCs is still emerging as specific OSFs
become identified and their signalling pathways in GCs/CCs
are elucidated. One of the challenges that remains is the
integration of this information into coherent physiological
mechanisms. This study was undertaken to investigate the
nature of the oocyte-GC/CC paracrine communication axis
specific to regulation of somatic cell proliferation, a pivotal
component of folliculogenesis. We hypothesised that this
communication axis probably involves a transforming growth
factor  (TGF) superfamily signalling system for the
following reasons. Firstly, mutations in some oocyte growth
factors belonging to this superfamily, namely growth
differentiation factor 9 (GDF9) and bone morphogenetic
protein 15 (BMP15), or in their receptors, have dramatic effects
on female reproductive phenotype, which suggests that such
signalling plays a critical role in ovarian folliculogenesis
(Dong et al., 1996; Galloway et al., 2000; Juengel and
McNatty, 2005). Interestingly, males carrying these same
mutations have apparently normal fertility, even though these
growth factors are also expressed in the hypothalamic-pituitary
axis and in very high levels in testis (Fitzpatrick et al., 1998;
Otsuka and Shimasaki, 2002). Secondly, certain TGF
superfamily members, in particular TGF1, TGF2, GDF9
and BMP15, can mimic the actions of oocytes on the GC/CC
functions outlined above, although it is now clear that this does
not necessarily mean a certain growth factor accounts for the
native OSF(s) normally mediating these processes (Dragovic
et al., 2005; Gilchrist et al., 2003; Gilchrist et al., 2004b;
Hussein et al., 2005; Vanderhyden et al., 2003). The essential
growth-promoting molecules and signalling pathways utilised
by oocytes remain to be determined.
The TGF superfamily receptor/signalling cascade is well
characterised (for reviews, see Massague et al., 2000;
Shimasaki et al., 2004). Extracellular ligands in the form of
homodimers or heterodimers, bind to either a type-I receptor
(commonly referred to as an activin receptor-like kinase; ALK)
or a type-II receptor and subsequent receptor heteromerisation,
leads to ALK phosphorylation followed by phosphorylation
of intracellular receptor-regulated signal transducers called
SMADs. Ligand-induced targeted gene transcription is
mediated by a heterodimeric complex of receptor-regulated
SMADs and receptor-independent co-SMADs, such as
SMAD4. Intracellular signalling by TGF superfamily growth
factors can be broadly divided into two distinct groups; those
utilising the TGF/activin signalling pathway, and those using
the BMP pathway. TGF/activin signalling typically involves
binding to ligand-specific type-II receptors, recruitment and
phosphorylation of ALK4 or ALK5, leading to activation of
the SMAD2 and SMAD3 proteins. By contrast, BMP ligand
binding to the BMP type-II receptor (BMPR-II) leads to
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phosphorylation of ALKs 2, 3 or 6, and subsequent activation
of SMAD1, SMAD5 and/or SMAD8 molecules (Massague et
al., 2000). Oocyte-derived BMP15 and BMP6 use the classic
BMP pathway; binding BMPR-II and ALK6, and activating the
SMAD1/5/8 pathway (Moore et al., 2003; Shimasaki et al.,
2004). By contrast, oocyte-secreted GDF9, a homologue of
BMP15, is an unusual member of the TGF superfamily in that
it uses a hybrid of the two signalling systems; GDF9 binds
BMPR-II (Vitt et al., 2002) but utilises the TGF type-I
receptor, ALK5 (Kaivo-Oja et al., 2005; Mazerbourg et al.,
2004), leading to activation of SMAD2 and SMAD3 signal
transducers (Kaivo-Oja et al., 2003; Kaivo-Oja et al., 2005;
Mazerbourg et al., 2004; Roh et al., 2003). Hence, even though
GDF9 binds a BMP type-II receptor it can be thought that it
induces a TGF-like intracellular response, in terms of SMAD
activation. GDF9 may also activate the MAPK pathway,
although at this stage it is unclear how this is mediated (Su et
al., 2003).
Of the numerous TGF superfamily members, oocytes are
known to express TGF1, TGF2, activins, GDF9, BMP15
and BMP6 (Juengel and McNatty, 2005), all of which, with the
sole exception of BMP6, exert mitogenic effects when added
in recombinant form to GCs in vitro. This study exploits a
bioassay of primary mouse GCs aspirated from antral follicles
and co-cultured with denuded oocytes, which enables scrutiny
of the actual native oocyte-secreted growth factors and allows
ablation of the signalling axis at various levels. Using
this bioassay, we have previously demonstrated that
immunoneutralisation of TGF1/2 has no effect on oocyte-
stimulated GC proliferation, but immunoneutralisation of
GDF9 eliminates approximately half of the mitogenic activity
of oocytes, demonstrating that oocytes secrete multiple
mitogens, one of which is GDF9 (Gilchrist et al., 2003;
Gilchrist et al., 2004b). The current study was conducted to
further investigate the nature of the paracrine signalling
system(s) from germ to neighbouring somatic cells, including
the receptors OSFs employ and the intracellular responses
invoked in GCs to stimulate proliferation.
Results
OSFs stimulate GC proliferation – comparison with
GDF9 and BMP6
Co-culture of oocytes with mural GCs led to a potent, dose-
dependent, stimulation of GC DNA synthesis, as assessed by
[3H]thymidine incorporation (Fig. 1A). To confirm that
increased GC 3H-incorporation is associated with GC
proliferation, we measured expression of the cell cycle
transcript Ccnd2 and found that mRNA levels were
significantly (P<0.01) increased to sixfold that of controls by
exposure to OSFs (Fig. 1B). GDF9 is known to be a potent GC
mitogen and a dose of 60 ng/ml appeared to be the saturation
point for this growth-promoting effect (Fig. 1A). We have
previously shown that oocyte-secreted GDF9 accounts for
some, but not all, of the oocyte mitogenic activity (Gilchrist et
al., 2004b). As little is known about the function of oocyte-
expressed BMP6, we compared the mitogenic effects of BMP6
to that of GDF9 and oocytes. Addition of BMP6 led to very
modest changes in mural GC DNA synthesis; 3-fold increase
at 400 ng/ml, compared with 40-fold for GDF9 at 60 ng/ml
(Fig. 1A). Furthermore, a BMP6-specific neutralising antibody
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(Fig. 1C). Together these results provide evidence that oocyte-
expressed BMP6 is unlikely to participate directly in the
growth-promoting effects of oocytes on GCs.
Interactions between OSFs and TGF superfamily
members
To examine possible interactions between GDF9 and other
putative oocyte-secreted mitogens, in the regulation of GC
DNA synthesis, mural GCs were treated with increasing
concentrations of recombinant mouse GDF9 either alone,
together with denuded oocytes (DOs), or together with TGF1,
which shares a common type-I receptor but uses a different
type-II receptor compared with GDF9 (Fig. 2). GDF9 was
an exceptionally potent stimulator of cell proliferation (c.f.
TGF1 or activin A; Fig. 3A), inducing 10-100-fold increases
in mural GC [3H]thymidine incorporation in a dose-dependant
manner (2-way ANOVA main effect, P<0.001; Fig. 2).
Denuded oocytes alone or TGF1 alone also significantly
increased mural GC [3H]thymidine incorporation (post-hoc
Tukey test; P<0.001), as expected, and this constant dose of
additional mitogen also augmented the effects of GDF9 at low
doses (Fig. 2). However, a significant GDF9  additional
mitogen interaction was observed (2-way ANOVA; P<0.001).
Although the effects of DOs or TGF1 were additive to GDF9
when at low doses, this additivity was lost at maximum and
near-maximum doses of GDF9 (>30 ng/ml). This was most
apparent with GDF9 + DO, where the additive effects of
oocytes were lost at just 15 ng/ml GDF9 or greater (P>0.05).
While TGF1 and GDF9 may appear to be additive at all doses
(Fig. 2), this was not statistically significantly at the highest
doses of GDF9. A similar result to GDF9 + TGF1 was
observed with GDF9 + activin A (data not shown). These
results indicate that a common receptor/signalling system is
employed by both GDF9 and oocyte-secreted factors, and
suggest that the type-II GDF9 receptor BMPR-II may be the
rate-limiting component of the signalling system used by
oocytes to promote mural GC proliferation.
OSFs signal through BMPR-II to promote granulosa cell
proliferation
To test whether BMPR-II is a rate-limiting component of
oocytes (#/125μl)
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Fig. 1. Oocyte stimulation of granulosa cell DNA synthesis –
comparison with GDF9 and BMP6. (A) Mural GCs were cultured
with increasing numbers of oocytes per well or increasing doses of
recombinant BMP6 or GDF9 and assessed for [3H]thymidine
incorporation after 24 hours. Points are means ± s.e.m. from
triplicate wells and are representative of three replicate experiments.
(B) Mural GCs were cultured alone or together with DOs (125
DOs/125-l well) for 6 hours, RNA was extracted, reverse
transcribed and subjected to real-time RT-PCR for Ccnd2. *mRNA
levels significantly increased with oocyte co-culture. (C) Mural GCs
were cultured alone, treated with BMP6 (50 ng/ml) or co-cultured
with 16 oocytes per well, each with and without a neutralising dose
(20 g/ml) of a BMP6 monoclonal neutralising antibody (NAb) or a
control IgG (20 g/ml). Columns represent means ± s.e.m. from
triplicate wells, representative of three replicate experiments. BMP6
NAb had no significant effect (P>0.05) on oocyte-stimulated GC
DNA synthesis.
GDF9 (ng/ml)





































Fig. 2. Interactions between GDF9 and TGF1 or oocyte-stimulated
granulosa cell DNA synthesis. Mural GCs were cultured with
increasing doses of mouse GDF9 either alone or in the presence of
DOs (16 DOs/125-l well) or human TGF1 (0.5 ng/ml). After 24
hours of culture the labelled thymidine incorporated into cells was
counted. Points are means ± s.e.m. from at least triplicate wells from
five replicate experiments. The stimulatory effects of TGF1 and
oocytes were additive to the stimulatory actions of GDF9 at low
doses of GDF9 [means with an asterisk are significantly different to
GDF9 alone at that dose (2-way ANOVA; P<0.01)], whereas this
additive effect was lost at higher doses of GDF9 (>8 ng/ml for DOs;














oocyte mitogenic signalling, we examined the capacity of a
known GDF9 antagonist, BMPR-II ECD, to neutralise the
mitogenic activity of oocytes (Fig. 3). The specificity of the
antagonistic action of the BMPR-II ECD was examined by
comparing its effectiveness against related TGF superfamily
mitogens: GDF9, activin A and TGF-1. As expected, the
BMPR-II ECD had no effect on TGF1-stimulated mural GC
DNA synthesis (P>0.05), was partially antagonistic against
activin A (P<0.05) and was a potent inhibitor of GDF9
(P<0.001; Fig. 3A), as previously reported (Moore et al., 2003;
Vitt et al., 2002). Interestingly, this reagent also dramatically
reduced oocyte-stimulated mural GC DNA synthesis (P<0.01;
Fig. 3A), and this occurred in a dose-dependent manner that
mirrored that observed for GDF9 (Fig. 3B). In both cases,
[3H]thymidine incorporation was approximately halved at 0.13
g/ml BMPR-II ECD (P<0.001) and reduced to control levels
at 2 g/ml. The results in Fig. 3 demonstrate that >90% of
oocyte mitogenic activity is mediated through BMPR-II.
Because it is known that there is a large degree of
redundancy within the superfamily of TGF receptors, we
went on to examine whether oocyte-secreted molecules may
also use other known type-II receptors, by testing a range of
TGF superfamily type-II receptor ECDs in our bioassay. Fig.
4A-C illustrates that ECDs of TGFR-II, ActR-IIA and ActR-
IIB are all effective at specifically antagonising the bioactivity
of their respective ligands (P<0.05), but neutralise <20% of
oocyte-stimulated activity (P>0.05; Fig. 4D), whereas,
consistent with the results in Fig. 3A, ~90% of oocyte
bioactivity was neutralised by the BMPR-II ECD (P<0.05).
Collectively, these experiments demonstrate that BMPR-II is
the main type-II TGF superfamily receptor transmitting the
oocyte paracrine signals that promote GC growth.
OSFs signal through BMPR-II to promote cumulus cell
proliferation
Because paracrine factors secreted by oocytes appear to
establish a morphogenic gradient in the ovarian follicle
(Hussein et al., 2005), presumably the main target cells for
OSFs are the granulosa cells immediately surrounding the
oocyte. In secondary follicles, these cells are the preantral GCs,
although oocytes do not appear to posses mitogenic activity at
this stage of development (Gilchrist et al., 2001), and in tertiary
follicles, these are the cumulus cells (CCs). To ensure that
oocyte paracrine signalling via BMPR-II has relevance in CCs,
we examined whether CCs express Bmpr2. Using real-time RT-
PCR, we found that CCs express levels of Bmpr2 mRNA
equivalent to those of MGCs (Fig. 5A). We also tested whether
the mitogenic effects of oocytes on CCs is mediated through
BMPR-II. CC DNA synthesis was stimulated by co-culture
with oocytes (P<0.05) and this response was completely
ablated by additional treatment with the BMPR-II ECD (Fig.
5B), which demonstrates that, as for mural GCs, this is the key
receptor for the transmission of oocyte paracrine effects in
CCs.
OSFs activate the TGF/activin intracellular SMAD
signalling pathway
Transduction of signals through BMPR-II requires formation
of a heteromeric complex with a type-I receptor(s), an ALK,
following ligand binding. Classical BMP signalling through
BMPR-II involves interaction with ALK2, ALK3 or ALK6
leading to activation of SMADs 1/5/8 (Shimasaki et al., 2004).
However, in the case of GDF9, signal transduction probably
requires the interaction of the BMPR-II with ALK5, leading to
SMAD 2/3 activation (Kaivo-Oja et al., 2005; Mazerbourg et
al., 2004). To determine the type-I receptor and intracellular
signalling molecules activated by oocytes, we co-cultured
oocytes with mural GCs and examined activation of mural
GC SMADs by use of SMAD-specific luciferase reporter
constructs and western blot analysis of phospho-SMAD
proteins. The CAGA promoter is activated by phosphorylated
SMAD3 upon cellular stimulation of ALKs corresponding to
the TGF/activin pathway, and the BMP-responsive element
(BRE) promoter is activated by phosphorylated SMAD1 or 5,
stimulated by BMPs (Mazerbourg et al., 2004). Treatment of
transfected mural GCs with TGF1, as expected, stimulated
Journal of Cell Science 119 (18)
Fig. 3. Specificity and potency of the BMP receptor-II ectodomain at
neutralising oocyte- and GDF9-stimulated mural GC DNA synthesis.
(A) Mural GCs were cultured with DOs (12 DOs/125-l well),
mouse GDF9 (40 ng/ml), human activin A (20 ng/ml), and human
TGF1 (0.5 ng/ml), in either the absence or the presence of a
maximum neutralising dose of BMP receptor-II ectodomain (BMPR-
II ECD; 2 g/ml). Bars represent means ± s.e.m. from at least
triplicate wells and are representative of three replicate experiments.
Asterisks represent significant neutralisation (P<0.01) caused by the
ECD. Control is mural GC alone or with mitogen. (B) Mural GCs
were cultured either with or without DOs (12 DOs/125-l well; )
or 40 ng/ml mouse GDF9 (), in either the absence or the presence
of increasing doses of BMPR-II ECD. Points are means ± s.e.m.
from at least triplicate wells, expressed as a fraction of the control
(mitogen with no ECD), and are representative of three replicate
experiments. An asterisk represents the lowest dose of BMPR-II
ECD that is significantly less than the 100% control (P<0.001).
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the luciferase reporter driven by the CAGA promoter, and this
was also dose-dependently stimulated with GDF9 (Fig. 6A),
which demonstrates that primary mouse GCs respond
intracellularly to GDF9 in the same manner as rat (Mazerbourg
et al., 2004) and human GCs (Kaivo-Oja et al., 2005).
Accordingly, treatment of mural GCs with GDF9 also induced
phosphorylation of SMAD2 molecules, as detected by western
blot (Fig. 6B). Consistent with oocyte-secretion of GDF9, co-
culture of mural GCs with oocytes also induced mural GC
SMAD2 phosphorylation (Fig. 6B).
To further examine the TGF superfamily signalling
pathways activated by oocytes, mural GCs transfected with
CAGA or BRE reporter constructs were co-cultured with
oocytes or treated with various TGF superfamily ligands. As
expected, CAGA-luciferase was stimulated by TGF1 and
GDF9 (P<0.01) but not by BMP6 and, in direct contrast, BRE-
luciferase was stimulated by BMP6 (P<0.01) but not by
TGF1 or GDF9 (Fig. 7). Consistent with the western blot
results, oocytes also activated the TGF/activin/GDF9
signalling pathway, as evidenced by stimulation of CAGA-
luciferase activity (P<0.01; Fig. 7A) but, surprisingly, oocytes
at the same concentration did not stimulate BRE-driven



























































Fig. 4. Specificity of oocyte-secreted
factors for BMPR-II within the
superfamily of TGF type-II receptors.
Mural GC thymidine incorporation was
stimulated with either (A) human
TGF1 (0.5 ng/ml), (B) mouse GDF9
(40 ng/ml), (C) human activin A
(10 ng/ml) or (D) 12 oocytes/well. Each
mitogen was also treated separately
with four different soluble receptor
ectodomains; BMPR-II, TGFR-II,
ActR-IIA and ActR-IIB, each at
2 g/ml. Bars are means ± s.e.m from
triplicate wells, expressed as a fraction
of the positive control (mitogen with no
ECD), and are representative of four
replicate experiments. An asterisk
represents significant antagonism
relative to the positive control (P<0.05).







































































Fig. 5. Expression of BMP receptor-II mRNA in cumulus cells and
BMP receptor-II ectodomain (BMPR-II ECD) neutralisation of
oocyte-stimulated cumulus cell DNA synthesis. (A) Mural granulosa
cells and cumulus-oocyte complexes were collected from antral
follicles, cumulus cells were generated by denuding cumulus-oocyte
complexes, RNA was extracted, reverse transcribed and subjected to
real-time RT-PCR. There was no significant difference between cell
types in the level of expression of BMPR-II mRNA.
(B) Oocytectomised complexes (OOX) were generated by
microsurgically removing the oocyte contents from cumulus-oocyte
complexes. OOX were cultured for 24 hours either alone, together
with 30 DOs/well, or with oocytes and 2 g/ml of BMPR-II ECD.
Columns are means ± s.e.m. from three replicate experiments.














increasing oocyte density from 60 to 240 DOs per well was a
small but significant (P<0.05) increase in BRE-driven
luciferase observed. Hence, OSFs do not appear to readily
activate the classic BMP signalling pathway.
OSFs promote GC and CC proliferation via the
TGF/activin signalling pathway
We next exploited an ALK 4/5/7 kinase inhibitor to provide
another line of evidence that oocytes stimulate GC and CC
growth by activating the type-I receptors characterised for
TGF/activin/GDF9 signalling. The inhibitor SB431542
specifically antagonises the kinase activities of ALKs 4, 5 and
7, without affecting the activities of ALKs 1, 2, 3 or 6 (Inman
et al., 2002). Accordingly, in our system, SB431542 dose-
dependently inhibited TGF1-stimulated mural GC CAGA-
luciferase (Fig. 8A), but had no effect on BMP6-stimulated
BRE-luciferase (Fig. 8B). Once this specificity was established
in our system, we went on to show that SB431542 also
completely abolished CAGA-luciferase activity stimulated by
either GDF9 or oocytes in transfected mural GCs (Fig. 8C).
Based on the results so far, we hypothesised that oocytes
promote GC growth by acting primarily through a GDF9-like
signalling pathway (i.e. BMPR-II + ALK 4/5 with SMAD 2/3
activation) and not through the BMP pathway. Therefore,
ablation of this pathway using the ALK 4/5/7 inhibitor should
prevent oocyte-stimulation of GC and cumulus cell DNA
synthesis. The results in Fig. 9 provide evidence to support this
hypothesis. Expression of cumulus cell Ccnd2 mRNA was
increased by treatment with GDF9 and oocytes (Fig. 9A);
mural GC [3H]thymidine incorporation was stimulated by
GDF9, TGF1 and oocytes (but not by BMP6; Fig. 9B); and
the effects of these mitogens were eliminated by treatment with
SB431542. Furthermore, oocyte-stimulation of mural GC
growth was dose-dependently inhibited with increasing
concentrations of the ALK inhibitor, in a pattern similar to
inhibition of GDF9-stimulated growth, and completely
eliminated proliferation (P<0.001) at doses as low as 1 M
(Fig. 9C).
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Fig. 6. Activation of granulosa cell SMAD2 and SMAD3 transducer
molecules by GDF9 and oocytes. (A) Mural GCs were transiently
transfected with a SMAD3-responsive CAGA-luciferase plasmid,
and subsequently left untreated, treated with 0.5 ng/ml TGF1, or
treated with increasing doses of GDF9 (or 293H: the negative v/v
control of conditioned medium from untransfected 293H cells) for 48
hours, and then relative luciferase activity was measured from cell
extracts. (B) Mural GCs were cultured for 90 minutes either alone
(control), co-cultured with oocytes (500 DOs/1-ml well), with human
activin A (50 ng/ml), or mouse GDF9 (40 ng/ml), then extracted
granulosa cell proteins were subjected to 10% SDS-PAGE and
western blotting using SMAD2 and phospho-SMAD2 antibodies.
Mural GC SMAD2 was phosphorylated by treatment with mGDF9,
oocytes and, to a lesser extent, activin A.
Fig. 7. Oocyte-paracrine factors signal through the TGF/activin
intracellular pathway, and not through the BMP pathway. Mural GCs
were transiently transfected during culture with either a SMAD3-
responsive CAGA-luciferase plasmid (A) or a SMAD1-responsive
BRE-luciferase reporter plasmid (B), then treated with various TGF
superfamily growth factors or were co-cultured with 60 oocytes/
250-l well. GDF9 was used at 40 ng/ml. TGF1 (0.5 ng/ml) is a
positive control for CAGA (and negative control for BRE), and
BMP6 (50 ng/ml) is a positive control for BRE (and negative
controls for CAGA). 293H is the GDF9 negative control: an
equivalent v/v of conditioned medium from untransfected 293H
cells. Columns represent means ± s.e.m. from four replicate
experiments. Oocytes significantly (P<0.01) increased mural GC
CAGA-luciferase, but not BRE-luciferase activity (P>0.05); asterisks
indicate significantly different to control (P<0.01).
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Discussion
Germ cell regulation of ovarian and testicular somatic cell
function is an essential component of normal gonadal function,
and elucidating the cellular and molecular mechanisms of this
newly recognised communication axis could have important
implications for the understanding and regulation of fertility
and developmental biology of the early embryo. The collective
results of this study indicate that the TGF superfamily growth
factors and receptor/signal transduction system are responsible
for mediating OSF stimulation of GC proliferation. BMPR-II
appears to be an indispensable receptor for the transmission of
mitogenic signals from the oocyte to somatic GCs, which
firmly establishes members of the TGF superfamily that
bind this receptor as being the primary mediators of
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Fig. 8. Inhibition of oocyte- and GDF9-stimulated SMAD3
activation using the ALK4/5/7 kinase inhibitor, SB431542. Mural
GCs were transiently transfected during culture with either a
SMAD3-responsive CAGA-luciferase or a SMAD1-responsive BRE-
luciferase reporter plasmid. (A) CAGA-luciferase was stimulated by
TGF1, which in turn was dose-dependently antagonised by
treatment with SB431542. The carrier, DMSO, at a v/v dose
equivalent to 0.5 M of SB431542, did not affect TGF-induced
mural GC CAGA-luciferase activity. (B) BMP6 (50 ng/ml)-
stimulated BRE-luciferase activity was not affected by a maximum
dose of 2 M SB431542. (C) Treatment of mural GCs with 0.5 M
SB431542 completely antagonised GDF9-activation (60 ng/ml) and
oocyte-activation (60 oocytes/well) of SMAD3-responsive CAGA
luciferase activity; asterisk indicates significantly different to control
(oocytes alone; P<0.05).
Fig. 9. Inhibition of oocyte- and GDF9-stimulated CC and mural GC
proliferation using the ALK 4/5/7 kinase inhibitor, SB431542.
(A) Cumulus cells (OOX) were treated with GDF9 (250 ng/ml) or
DOs (0.8/l), with or without 4 M SB431542 and cultured for 6
hours, and Ccnd2 mRNA levels were examined using real-time RT-
PCR. Columns are means ± s.e.m. from six replicate experiments and
columns with different superscripts are significantly different
(P<0.05). (B) Mural GCs were cultured for 24 hours and thymidine
incorporation was stimulated with either 20 ng/ml GDF9, 0.5 ng/ml
TGF1, 16 DOs/well or 50 ng/ml BMP6, all of which, in turn, were
antagonised by SB431542 at 1.0 M. An equivalent dose of the
SB431542 carrier DMSO did not affect ligand-stimulated mural GC
DNA synthesis. Columns are means ± s.e.m. from triplicate wells
and are representative of three replicate experiments; asterisks
indicate significantly different to control (mitogen alone; P<0.001).
(C) Oocyte (14/well)- and GDF9 (20 ng/ml)-stimulated mural GC
DNA synthesis were inhibited in a dose-dependent manner with
increasing concentrations of SB431542. Points are means ± s.e.m.
from triplicate wells and are representative of three replicate
experiments. Asterisks represent the lowest dose of SB431542 that is













determined that OSFs do not employ BMPR-II to activate
classic BMP signalling in the stimulation of GC proliferation,
and ligands that do stimulate such signalling in GCs are not
particularly mitogenic. Rather, mitogenic activity exerted by
the oocyte relies on a hybrid of classic TGF/activin and BMP
signalling, characterised by a receptor combination of BMPR-
II and ALK4/5 followed by activation of the SMAD 2/3
intracellular cascade. This unique signalling hybrid can be
stimulated by GDF9 (Kaivo-Oja et al., 2005; Mazerbourg et
al., 2004; Roh et al., 2003), but this factor alone does not
account for the total mitogenic capacity of a whole oocyte
(Gilchrist et al., 2004b).
BMPR-II is expressed in GCs at early stages of
folliculogenesis, in primordial ruminant follicles and primary
rodent follicles, and continues to be expressed throughout
subsequent stages of folliculogenesis (Juengel and McNatty,
2005). Previously, it was unclear whether GCs that differentiate
into CCs continue to express BMPR-II as preliminary
observations suggested expression levels may be low in this
GC subtype (Erickson and Shimasaki, 2003). Our current
results demonstrate that CCs from large antral mouse follicles
express equivalent levels of BMPR-II mRNA as their
companion mural GCs, which indicates that expression of this
receptor is not lost upon CC differentiation. This finding is
important because during the antral phase of folliculogenesis,
when the bioactivities of OSFs are most potent (Gilchrist et al.,
2004a), the primary recipients of OSFs are CCs and not mural
GCs (Hussein et al., 2005), which largely accounts for their
substantially higher mitogenic potential (Li et al., 2000).
The BMPR-II ECD is a known functional antagonist of the
recombinant forms of the key known OSFs that utilise BMPR-
II, namely GDF9 and BMP15 (Moore et al., 2003; Vitt et al.,
2002), and may antagonise the many other BMP ligands
utilising this receptor, depending on the binding affinity of the
individual ligand. In a previous study (Dragovic et al., 2005),
we showed that the BMPR-II ECD completely blocks CC
expansion induced by GDF9, but only partly prevents oocyte-
induced expansion. In the current study, addition of the BMPR-
II ECD to oocyte-GC co-cultures led to a dose-dependent
suppression of oocyte-induced GC DNA synthesis. The
neutralisation profiles of oocyte- and GDF9-induced DNA
synthesis generated by the BMPR-II ECD were highly
comparable, in which mitogenic activity of both was
completely eliminated at moderate doses of antagonist. This
approach of neutralising oocyte activity using the BMPR-II
ECD was equally effective whether using CCs or mural GCs.
Together these results suggest that the totality of oocyte-
secreted mitogenic activity depends upon binding to BMPR-II.
Consistent with the notion of BMPR-II being a key receptor
in OSF signalling, is the finding that at sub-maximal doses of
GDF9, oocytes and GDF9 have an additive effect on mural GC
DNA synthesis, whereas this additivity is lost at saturating
GDF9 concentrations. By contrast, TGF1 and GDF9, which
use different type-II receptors but share a common type-I
receptor (ALK5), have additive mitogenic effects, even at
maximal GDF9 doses. Therefore, BMPR-II, and not ALK5,
availability is rate-limiting, providing further support to our
hypothesis that access to BMPR-II is a key determinant of OSF
efficacy (Hussein et al., 2005). To examine whether OSFs may
also bind other TGF superfamily type-II receptors, we
compared a range of type-II receptor ECDs. The TGF and
activin type-II receptor ECDs had marginal effects on oocyte
mitogenic activity. However, the BMPR-II ECD was by far the
most effective of the ECDs at antagonising oocyte mitogenic
activity, providing a further line of evidence that BMPR-II is
the key type-II receptor transmitting the paracrine actions of
oocytes to GCs/CCs.
Based on the hypothesis that, at a minimum, GDF9, BMP15
and BMP6 are the key OSFs that could signal through BMPR-
II, we next went on to examine activation by oocytes of the
classic TGF superfamily signalling cascades in GCs.
Interestingly, our luciferase and western blot results indicate
that oocytes appear to activate primarily the TGF/activin
pathway, one not stimulated by BMPs. Oocytes strongly
stimulated CAGA-luciferase activity, which is activated by
phosphorylated SMAD3, but at best marginally stimulated
BRE-luciferase, which is SMAD1 responsive. Furthermore,
oocyte stimulation of CAGA-luciferase activity was
completely eliminated using the ALK4/5/7 kinase inhibitor,
SB431542. Oocyte activation of the SMAD2/3 pathway is not
surprising given oocyte-secreted GDF9 is a key GC mitogen
(Gilchrist et al., 2004b), and it is now known that GDF9 utilises
ALK5 to activate SMAD2/3 molecules (Kaivo-Oja et al., 2003;
Kaivo-Oja et al., 2005; Mazerbourg et al., 2004; Roh et al.,
2003). Oocytes also express TGF1 and TGF2, but it appears
that biologically active forms of these molecules are not
secreted by the immature or maturing oocyte and these may
represent maternally stored transcripts to be translated post-
fertilisation (Gilchrist et al., 2003). If mouse oocytes activate
only the SMAD2/3 pathway and not the SMAD1/5/8 pathway
in GCs (present study), then inhibition specifically of this
signalling cascade should prevent oocyte-stimulated GC DNA
synthesis. Indeed, the results from the current study
demonstrate this to be the case; SB431542, which has no effect
on BMP-activation of SMAD1/5/8, dose-dependently
antagonised the growth-promoting effects of oocytes on GCs.
These results support the conclusion that oocyte stimulation of
GC DNA synthesis is mediated via the GDF9/TGF signalling
system, that is, BMPR-II dimerising with ALK4 and/or -5 and
activating the SMAD 2/3 pathway, and that BMP intracellular
signalling plays a minor role in this communication axis.
This cell-signalling pathway may also be relevant in non-
ovarian tissues. The receptors and SMAD signalling molecules
examined here are expressed widely throughout the body;
however, GDF9 and BMP15 expression is restricted to the
gametes and to the hypothalamic-pituitary axis (Aaltonen et al.,
1999; Fitzpatrick et al., 1998). A physiological role for GDF9
and BMP15 in the testis or hypothalamic-pituitary axis has not
been described, possibly as males with mutations in these
genes appear completely normal. BMP15 has been shown to
stimulate selectively FSH expression by pituitary cells (Otsuka
and Shimasaki, 2002). The paracrine signalling system
described here between oocytes and their neighbouring
somatic cells, could well have parallels in the testis as
spermatocytes express very high levels of GDF9 (Fitzpatrick
et al., 1998) and paracrine communication between developing
spermatocytes and Sertoli cells is vitally important for testis
function and male fertility.
The very weak or complete lack of activation of the BMP
intracellular pathway by mouse oocytes is perhaps surprising
because certain BMPs are regarded as key OSFs. Although it
is now widely recognised that the regulation of ovarian
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granulosa cell growth and differentiation by OSFs is a critical
process in ovarian biology (for reviews, see Eppig, 2001;
Gilchrist et al., 2004a; McNatty et al., 2004), the mechanisms
by which this occurs, including the exact identities of the
oocyte-secreted molecules mediating this process, are not yet
fully understood (Gilchrist et al., 2004a; Vanderhyden et al.,
2003). GDF9, BMP15 and BMP6 are currently regarded as the
best candidate molecules responsible for oocyte regulation of
most GC processes. GDF9 is an exceptionally potent GC
mitogen (Elvin et al., 1999; Gilchrist et al., 2004b; Hayashi et
al., 1999; Hickey et al., 2005; Vitt et al., 2000) and, based on
immunoneutralisation experiments using an antibody against
GDF9, we have previously proposed that oocyte-derived GDF9
accounts for approximately half of the total mitogenic activity
of mouse oocytes (Gilchrist et al., 2004b). The identity of the
remaining half is currently unknown although TGF1 or
TGF2 are most unlikely to have a role (Gilchrist et al., 2003;
Gilchrist et al., 2004b). Oocyte-secreted BMP6 also seems
most unlikely as at best it is weakly mitogenic in GCs (Otsuka
et al., 2001) and, furthermore, we show that it does not
stimulate the mitogenic pathways oocytes utilise to promote
GC proliferation (present study). However, BMP15 seems a
likely candidate OSF as recombinant human BMP15
stimulates rat GC proliferation (Otsuka et al., 2000) and
BMP15 is required for early follicular progression in sheep
(Galloway et al., 2000).
Complete antagonism of oocyte-stimulated GC DNA
synthesis by the BMPR-II ECD in the current study, which was
not achieved using a GDF9-specific neutralising antibody in a
previous study (Gilchrist et al., 2004b), suggests a key role for
a BMPR-II-binding molecule other than GDF9. However, even
though BMP15 utilises BMPR-II, a BMP15 homodimer is
unlikely to be involved as this molecule signals through
SMAD1/5/8 (Moore et al., 2003), and the current results
demonstrate that oocyte-stimulation of GC DNA synthesis is
exclusively mediated through SMAD2/3. This failure of mouse
oocytes to activate the GC BMP signalling cascade is perhaps
clarified by new evidence which demonstrates that fully
processed mouse BMP15 cannot be secreted by cell lines as an
intact homodimer (Hashimoto et al., 2005), which explains
why bioactive recombinant mouse BMP15 has never been
produced. Whether mouse oocyte secretion of a BMP15
homodimer is atypical within the TGF superfamily, in some
manner, remains to be determined, although this would be
compatible with our current results, whereby (1) mouse
oocytes fail to mimic recombinant human BMP15 by activating
the BMP signalling pathway, and (2) ablation of SMAD2/3
signalling completely eliminates the growth-promoting effects
of oocytes. Perhaps an oocyte-secreted GDF9/BMP15
heterodimer constitutes an important component of the total
mitogenic activity of oocytes, and this is achieved via
signalling through the same receptor/signalling cascade as used
by GDF9 homodimers. To date very little is known of
GDF9/BMP15 heterodimer biology including how it signals;
however, a heterodimer of recombinant proteins has been
demonstrated (Liao et al., 2003) and, furthermore, recombinant
GDF9 and BMP15 interact substantially to stimulate GC
growth, as well as to regulate steroidogenesis and inhibin
production in vitro (McNatty et al., 2005a; McNatty et al.,
2005b). Further studies are required to investigate these
hypotheses.
In conclusion, this study has determined the requisite
signalling pathways by which oocyte paracrine signals
stimulate ovarian granulosa cell proliferation. This signalling
is primarily achieved through GDF9 and GDF9-related
molecules using the GDF9/TGF receptor and intracellular
signal transduction cascade. BMPR-II appears to be an
indispensable, and possibly a rate-limiting, type-II receptor on
GCs/CCs for transmission of the growth-promoting effects of
oocytes. OSFs elicit a TGF-like intracellular response in GCs,
and surprisingly, do not appear to activate the BMP pathway.
Participation of the TGF/activin/GDF9 type-I receptors,
ALK4 and/or 5, and activation of the SMAD2/3 pathway, are
indispensable for oocyte-stimulation of GC proliferation.
Although the exact composition of the oocyte-secreted
molecules promoting GC growth is not yet fully resolved,
results from this study suggest GDF9 plus a GDF9-related
molecule(s) account for most, if not all, mouse oocyte
mitogenic activity. Elucidation of the molecular and cellular
processes by which germ cells regulate the function of their
companion somatic cells is vitally important to our basic
understanding of mechanisms of cell-to-cell communication in
the ovary and testis, and, furthermore, is likely to have
implications for fertility management and diseases of impaired
folliculogenesis.
Materials and Methods
Oocyte-secreted factor bioassay: mural GC DNA synthesis
Experimental procedures used in this study for the bioassay of mouse oocyte
mitogens, including the collection, preparation and co-culture of mural GCs with
denuded oocytes (DOs), have been previously described (Gilchrist et al., 2003;
Gilchrist et al., 2001; Gilchrist et al., 2004b). This study was approved by local
Animal Ethics Committees. In brief, ovaries were collected from immature (21-26
days old) 129/SV mice 46 hours after priming with 5 IU of equine chorionic
gonadotrophin (Folligon®, Intervet, Castle Hill, Australia). Mural GCs and
cumulus-oocyte complexes were collected by puncturing large antral follicles and
DOs were generated by vortexing cumulus-oocyte complexes for 3-4 minutes to
dissociate cumulus cells. Mural GCs and DOs were washed twice in protein-free
culture medium: bicarbonate-buffered tissue culture medium-199 with supplements
(Gilchrist et al., 2001). Depending on the individual experiments, mural GCs
(2105 viable and non-viable cells/ml), DOs, hormones, reagents and media were
added to wells of 96-well plates (Falcon) to give a final volume of 125 l. Within
each experiment, all treatments were carried out in at least duplicate wells and each
experiment was replicated on at least three occasions. Cells were cultured in an
atmosphere of 37°C, 96% humidity in 5% CO2 in air for 18 hours, followed by a
further 6 hour pulse of 15.4 kBq tritiated thymidine ([3H]thymidine, ICN) under the
same conditions. Following culture, mural GCs were harvested, and incorporated
[3H]thymidine was quantified using a scintillation counter as an indicator of the
proportion of cells in S-phase, hence providing an indication of the level of mural
GC DNA synthesis and proliferation (Lee et al., 2001).
Oocyte-secreted factor bioassay: cumulus cell DNA synthesis
To determine whether oocyte-secreted factors also stimulate cumulus cell DNA
synthesis via BMPR-II, the contents of each oocyte were microsurgically removed
from the cumulus-oocyte complex as previously described (Buccione et al., 1990;
Li et al., 2000). The resulting oocytectomised complexes (OOX) consist of a hollow
zona pellucida surrounded by several layers of cumulus cells. Groups of 20 OOX
were assigned to the following treatments: (1) cumulus cell control (OOX alone),
(2) cumulus cells co-cultured with DOs (OOX + DO), or (3) OOX + DO + BMPR-
II ECD (as described below), and each treatment was carried out in duplicate wells
of 125 l. Cumulus cell culture and assessment of DNA synthesis was as described
above.
Oocyte-secreted factor bioassay: mural GC phospho-SMAD
reporter assay
Luciferase reporter constructs responsive to specific phosphorylated SMADs were
used to detect the activation of mural GC SMAD proteins by DOs or by recombinant
forms of putative OSFs. Mural GCs were collected and processed as described
above, except cells were collected in HEPES-199 + 2% FCS (Trace Biosciences,
Castle Hill, Australia) and were washed twice in bicarbonate buffered DMEM (MP













transferred to individual wells of a 96-well plate (Falcon) and cultured at 1.6105
cells/ml. After 4 hours of culture, cells were transiently transfected with 50 ng of
luciferase reporter construct DNA using Fugene 6 (Roche Diagnostics, Castle Hill,
Australia). Eighteen hours after transfection, medium was aspirated from cells and
replaced with DMEM supplemented with 0.1% FCS. Specific ligands were added
to cells at this point (see below) and the culture period extended for a further 48
hours. Experiments were terminated by removing media from wells and freezing
plates at –20°C. To harvest cells, 100 l of lysis buffer was added to each well and
plates were incubated at room temperature on a rocking platform for 20 minutes.
20 l of cell lysate was used for measurement of luciferase activity using a
Galaxystar luminometer (GMB Labtechnologies, Offenburg, Germany).
Bioassays: experimental reagents and treatments
Mural GCs were treated with a number of growth factors: TGF1, activin A, BMP6
(all recombinant human from R&D Systems, MN), as well as mouse GDF9 and
DOs. Fully processed, bioactive recombinant mouse GDF9 was produced and
quantified in house (Gilchrist et al., 2004b; Kaivo-Oja et al., 2003), in stably
transfected human embryonic kidney-293H cells and partially purified using
hydrophobic interaction chromatography (HIC), as recently described (Hickey et
al., 2005). Control conditioned medium (labelled ‘293H’) from untransfected 293H
cells (Gibco Life Technologies, Paisley, UK) was produced and HIC-purified under
conditions identical to those used for the production of GDF9.
In an attempt to identify GC receptors used by oocyte-secreted mitogens to
promote proliferation, experiments were designed to counter the growth-promoting
activity of the mitogens using solubilised forms of known TGF superfamily type-
II receptors. The solubilised receptor ectodomains (ECDs; purchased from R&D
Systems) are recombinant chimeric proteins consisting of the extracellular portion
of a type-II receptor fused to the Fc region of human IgG. The BMPR-II ECD can
antagonise the bioactivity of recombinant mGDF9, hBMP15 and hBMP7 on
granulosa cells and it has only partial neutralising activity against activin-A (Moore
et al., 2003; Vitt et al., 2002). In neutralisation experiments, BMPR-II ECD,
TGFR-II ECD, ActR-IIA ECD and ActR-IIB ECD were pre-incubated at 2 g/ml
with mitogen for 30 minutes in culture wells, prior to addition of mural GC.
To examine the TGF superfamily type-I receptors employed by oocyte paracrine
factors, their intracellular signalling and mitogenic activity were antagonised by
treatment with SB431542 (generously donated by GlaxoSmithKline, Stevenage,
UK). This small molecule inhibitor acts as a competitive ATP-binding site kinase
inhibitor that is highly specific for ALKs 4, 5 and 7, and has no effect on ALKs 1,
2, 3 or 6 or other cellular kinases when used at <10 M (Inman et al., 2002).
SB431542 antagonises the bioactivity of activin and TGF (Inman et al., 2002) but
its effects on activity of other members of the TGF superfamily or on oocytes are
currently unknown. A BMP6-neutralising antibody (R&D Systems) was also
employed which, in this culture system, is effective at antagonising BMP6
suppression of FSH-induced progesterone production (Ritter and Gilchrist, 2004).
Immunoblot analysis of phospho-SMAD proteins
To generate protein extracts for SMAD analyses, mural GCs were cultured as
described above with the following exceptions: cells were cultured at 1106
cells/ml in 1 ml of medium in 48-well plates (Falcon, Franklin Lakes NJ), and
oocytes were co-cultured with mural GCs at 500 DOs/ml. After 90 minutes of
culture, oocytes were removed, mural GCs were collected, washed in PBS, lysed in
Laemmli protein extraction buffer and sonicated before western blot analysis. This
experiment was replicated three times. Techniques for immunoreactive analysis of
SMAD proteins have already been described (Kaivo-Oja et al., 2003). Briefly,
membranes were blocked in 5% milk in Tris-buffered saline in the presence of NP-
40, and treated with primary antibodies (anti-SMAD2 and anti-phospho-SMAD2
[PS2], kindly donated by Peter ten Dijke, Amsterdam, The Netherlands) overnight
at 4°C. Secondary antibody (Jackson’s peroxidase-conjugated anti-IgG anti-rabbit)
treatment was performed at room temperature for 1 hour. Immunoreactive proteins
were detected using Amersham Biosciences’ ECL reagents.
Detection and quantification of mRNA in cumulus and
granulosa cells
Real-time reverse transcription PCR (RT-PCR) was used to determine whether OSFs
increase Ccnd2 mRNA levels in cumulus and granulosa cells as well as to quantify
the level of Bmpr2 mRNA expressed in cumulus cells relative to GCs. Pure
populations of CCs and mural GCs were collected and OOX were generated, as
described above. RNA was extracted using TriReagent for Bmpr2 (Sigma, St Louis,
MO) or a Micro RNA isolation kit for Ccnd2 (Qiagen, Clifton Hill, Australia),
quantified using a Ribogreen assay (Molecular Probes, Eugene, OR), and reverse
transcribed to cDNA using Superscript-II (Life Technologies, Grand Island, NY).
cDNA was amplified by PCR using specific primers for Rpl19 housekeeping control
gene (Rpl19 control for Bmpr2, forward primer, 5 GTG CTT CCG ATT CCA GAG
TTC T 3; reverse primer, 5 TCG TGT TCC TGA GGG TGA AAG 3; or Rpl19
control for Ccnd2, forward primer, 5GAA AGG TGC TTC CGA TTC CA 3;
reverse primer, 5 TGA TCG CTT GAT GCA AAT CC 3) and genes of interest:
Ccnd2 (forward primer 5 TGC ATT TAC ACC GAC AAC TCT GT 3; reverse
primer 5 CTT GCG AAG GAT GTG CTC AA 3) and Bmpr2 (forward primer, 5
GAA CTC ATG ATG ATA TGG GAG AGA AAC 3; reverse primer, 5TGG CAC
ACG CCT ATT ATG TGA 3). The quantity of PCR amplicons was detected in real
time using an Applied Biosystems 5700 Real Time light cycler using sybergreen as
the detection reagent. Ccnd2 mRNA levels were expressed relative to a calibrator
and normalised to Rpl19 using the standard curve method as outlined by Applied
Biosystems. Bmpr2 expression levels in CCs and mural GCs were also expressed
relative to a calibrator and normalised to steady state Rpl19 housekeeping gene
expression using the comparative Ct method according to Applied Biosystems.
Statistical analyses
Data were generally log transformed and treatment effects were examined using
one-way or two-way ANOVAs and differences between treatment means tested
using Tukey (pairwise multiple comparisons) or Dunnett’s method (multiple
comparisons versus a control) post-hoc comparisons. A P value of <0.05 was
considered statistically significant unless otherwise stated.
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